SCHEDULE 13G/A: Frazier Life Sciences Funds Divest Entire Stake in AN2 Therapeutics

Frazier Life Sciences Public Fund and affiliated entities have reported a complete divestment of their beneficial ownership in AN2 Therapeutics, Inc. common stock as of December 31, 2024.

Summary

• This is an Amendment No. 1 to a Schedule 13G filing by Frazier Life Sciences Public Fund, L.P. and several affiliated entities and individuals.
• The filing indicates that as of December 31, 2024, the reporting persons collectively hold 0.00 shares of AN2 Therapeutics, Inc. common stock, representing 0.0% of the class.
• This signifies a complete divestment of their previously reported beneficial ownership in AN2 Therapeutics, Inc.
• The filing was made pursuant to Rule 13d-1(c) of the Securities Exchange Act of 1934, indicating a group filing.

Sentiment

Score: 3

Explanation: The complete divestment by a significant institutional investor group is a negative signal, indicating a lack of confidence or a strategic shift away from the company.

Negatives

• The complete divestment of shares by Frazier Life Sciences Public Fund and its affiliated entities could be interpreted as a loss of confidence in AN2 Therapeutics, Inc. by a significant institutional investor.
• This action removes a large institutional holder from the company's shareholder base.

Risks

• The full divestment by a major institutional investor group may signal underlying concerns about AN2 Therapeutics, Inc.'s future prospects, potentially impacting investor sentiment and share price.
• A significant reduction in institutional ownership can sometimes lead to increased stock volatility or reduced liquidity.

Future Outlook

NA

Industry Context

This filing reflects a specific investment decision by Frazier Life Sciences, a venture capital firm specializing in life sciences. While not indicative of broader industry trends on its own, significant divestments by specialized funds can sometimes precede or reflect shifts in sector-specific investment strategies or perceptions of sub-sector valuations within biotechnology.

Stakeholder Impact

• Shareholders: The complete divestment by a major institutional investor could lead to negative market sentiment and potential downward pressure on AN2 Therapeutics, Inc.'s share price.
• Potential Investors: May view the divestment as a red flag, potentially deterring new investment.

Key Dates

Recommendation

Keywords

AN2 Therapeutics, Frazier Life Sciences, Schedule 13G/A, beneficial ownership, institutional investor, divestment, common stock, SEC filing, biotechnology, pharmaceuticals